B

Bioatla Inc
NASDAQ:BCAB

Watchlist Manager
Bioatla Inc
NASDAQ:BCAB
Watchlist
Price: 1.71 USD -14.07%
Market Cap: 82.7m USD
Have any thoughts about
Bioatla Inc?
Write Note

Bioatla Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioatla Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioatla Inc
NASDAQ:BCAB
Cash & Cash Equivalents
$111.5m
CAGR 3-Years
-22%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash & Cash Equivalents
$7.3B
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Cash & Cash Equivalents
$5B
CAGR 3-Years
5%
CAGR 5-Years
-12%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Cash & Cash Equivalents
$9B
CAGR 3-Years
-9%
CAGR 5-Years
-5%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash & Cash Equivalents
$6.5B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash & Cash Equivalents
$2B
CAGR 3-Years
-16%
CAGR 5-Years
8%
CAGR 10-Years
12%

See Also

What is Bioatla Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
111.5m USD

Based on the financial report for Dec 31, 2023, Bioatla Inc's Cash & Cash Equivalents amounts to 111.5m USD.

What is Bioatla Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
59%

Over the last year, the Cash & Cash Equivalents growth was -48%. The average annual Cash & Cash Equivalents growth rates for Bioatla Inc have been -22% over the past three years , 59% over the past five years .

Back to Top